Enimmune Corporation (TPEX:6564)
18.70
-0.65 (-3.36%)
Apr 29, 2026, 1:24 PM CST
Enimmune Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -164.35 | -157.55 | -223.74 | -247.96 | -47.25 | Upgrade
|
| Depreciation & Amortization | 8.94 | 7.44 | 7.6 | 8.2 | 8.49 | Upgrade
|
| Other Amortization | 0.14 | 0.15 | 0.15 | 0.15 | 0.14 | Upgrade
|
| Stock-Based Compensation | 1.75 | 3.03 | 3.69 | 2.27 | - | Upgrade
|
| Provision & Write-off of Bad Debts | -1.58 | -0.15 | 0.17 | 4.92 | 0.07 | Upgrade
|
| Other Operating Activities | -17.35 | 9.31 | -13.89 | -19.33 | 0.02 | Upgrade
|
| Change in Accounts Receivable | -0.02 | -0.45 | -7.47 | 17.46 | 1.19 | Upgrade
|
| Change in Inventory | 1.11 | -6.64 | 44.78 | -8.48 | -9.79 | Upgrade
|
| Change in Accounts Payable | -0.36 | -15.17 | 14.09 | -6.39 | -6.75 | Upgrade
|
| Change in Unearned Revenue | - | - | - | - | 1.72 | Upgrade
|
| Change in Other Net Operating Assets | 28.46 | 16.24 | 36.5 | 48.53 | -19.38 | Upgrade
|
| Operating Cash Flow | -143.25 | -143.78 | -138.13 | -200.64 | -71.55 | Upgrade
|
| Capital Expenditures | -4.18 | -0.47 | - | -0.35 | -2.98 | Upgrade
|
| Sale (Purchase) of Intangibles | - | - | - | - | -0.43 | Upgrade
|
| Investment in Securities | -24.5 | - | 88 | 123.49 | 93.5 | Upgrade
|
| Other Investing Activities | 2.93 | -3.17 | -0.14 | -23.21 | 0.01 | Upgrade
|
| Investing Cash Flow | -25.75 | -3.64 | 87.86 | 99.94 | 90.1 | Upgrade
|
| Short-Term Debt Issued | 25 | 60 | 20 | 20 | - | Upgrade
|
| Long-Term Debt Issued | 38.56 | 6.11 | - | - | - | Upgrade
|
| Total Debt Issued | 63.56 | 66.11 | 20 | 20 | - | Upgrade
|
| Long-Term Debt Repaid | -10.35 | -4.06 | -3.97 | -3.95 | -3.94 | Upgrade
|
| Net Debt Issued (Repaid) | 53.21 | 62.05 | 16.03 | 16.05 | -3.94 | Upgrade
|
| Issuance of Common Stock | - | 202.04 | - | 220.35 | - | Upgrade
|
| Other Financing Activities | -156.31 | - | - | 144.68 | - | Upgrade
|
| Financing Cash Flow | -103.1 | 264.09 | 16.03 | 381.08 | -3.94 | Upgrade
|
| Foreign Exchange Rate Adjustments | -10.42 | 8.34 | -0.04 | -4.59 | - | Upgrade
|
| Net Cash Flow | -282.52 | 125.01 | -34.28 | 275.79 | 14.61 | Upgrade
|
| Free Cash Flow | -147.43 | -144.25 | -138.13 | -200.98 | -74.53 | Upgrade
|
| Free Cash Flow Margin | -305.91% | -361.39% | -317.59% | -106.67% | -67.86% | Upgrade
|
| Free Cash Flow Per Share | -2.04 | -2.02 | -2.10 | -3.15 | -1.24 | Upgrade
|
| Cash Interest Paid | 3.92 | 2.12 | 0.92 | 0.28 | 0.21 | Upgrade
|
| Levered Free Cash Flow | -107.27 | -74.54 | -53.27 | -127.9 | -61.94 | Upgrade
|
| Unlevered Free Cash Flow | -104.76 | -73.16 | -52.65 | -127.7 | -61.79 | Upgrade
|
| Change in Working Capital | 29.2 | -6.02 | 87.9 | 51.12 | -33.01 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.